BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20167138)

  • 1. Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma.
    Pfaar O; Klimek L; Sager A; Bräutigam M
    Am J Rhinol Allergy; 2010; 24(3):220-5. PubMed ID: 20167138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts.
    Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
    Clin Exp Allergy; 2007 Mar; 37(3):434-40. PubMed ID: 17359393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of the efficacy of specific immunotherapy with house-dust mite extracts in adults with allergic rhinitis and/or asthma].
    Polzehl D; Keck T; Riechelmann H
    Laryngorhinootologie; 2003 Apr; 82(4):272-80. PubMed ID: 12717603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients.
    Pfaar O; Sager A; Robinson DS
    Pediatr Allergy Immunol; 2015 May; 26(3):280-286. PubMed ID: 25640879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts.
    Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
    Int Arch Allergy Immunol; 2006; 139(2):153-8. PubMed ID: 16374026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
    Gallego MT; Iraola V; Himly M; Robinson DS; Badiola C; García-Robaina JC; Briza P; Carnés J
    Int Arch Allergy Immunol; 2010; 153(1):61-9. PubMed ID: 20357486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study.
    Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C
    Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of allergic rhinitis caused by grass pollen or house-dust mites in Spain.
    Valero A; Justicia JL; Antón E; Dordal T; Fernández-Parra B; Lluch M; Montoro J; Navarro AM
    Am J Rhinol Allergy; 2011; 25(4):e123-8. PubMed ID: 21310119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice.
    Ferrés J; Justicia JL; García MP; Muñoz-Tudurí M; Alvà V
    Allergol Immunopathol (Madr); 2011; 39(3):122-7. PubMed ID: 20570032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis.
    Riechelmann H; Schmutzhard J; van der Werf JF; Distler A; Kleinjans HA
    Am J Rhinol Allergy; 2010; 24(5):e104-9. PubMed ID: 21244725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ; Antvelink JB; Luwema RA
    Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule.
    Colás C; Monzón S; Venturini M; Lezaun A
    J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.